Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $408.0 million.

  • Lyell Immunopharma's Liabilities and Shareholders Equity fell 34.12% to $408.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 36.93%. This contributed to the annual value of $490.9 million for FY2024, which is 34.55% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Liabilities and Shareholders Equity is $408.0 million, which was up 5.84% from $385.5 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Liabilities and Shareholders Equity peaked at $1.2 billion during Q2 2021, and registered a low of $385.5 million during Q2 2025.
  • Over the past 3 years, Lyell Immunopharma's median Liabilities and Shareholders Equity value was $654.1 million (recorded in 2024), while the average stood at $631.1 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Liabilities and Shareholders Equity increased by 24.13% in 2021, and later crashed by 41.08% in 2025.
  • Lyell Immunopharma's Liabilities and Shareholders Equity (Quarterly) stood at $1.1 billion in 2021, then declined by 16.84% to $937.6 million in 2022, then declined by 20.00% to $750.0 million in 2023, then slumped by 34.55% to $490.9 million in 2024, then tumbled by 34.12% to $408.0 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $408.0 million for Q3 2025, versus $385.5 million for Q2 2025 and $429.8 million for Q1 2025.